Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Prescient & Strategic Intelligence Private Limited | PRODUCT CODE: 1159521

Cover Image

PUBLISHER: Prescient & Strategic Intelligence Private Limited | PRODUCT CODE: 1159521

Benign Prostatic Hyperplasia (BPH) Treatment Market Size Analysis Report by Type (Drug Treatment, Surgical Treatment), End User (Home Healthcare, Hospitals & Clinics) - Industry Analysis Forecast to 2030

PUBLISHED:
PAGES: 378 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 4900
Printable PDF (Group User License)
USD 6400
Printable PDF (Enterprise License)
USD 8400

Add to Cart

According to the latest market research study published by P&S Intelligence, the BPH treatment market accounted for $11,892.8 million revenue in 2021, which is set to touch $18,837.7 million by 2030, progressing at a 5.2% CAGR from 2021 to 2030. This is owing to the growing cases of BPH, soaring preference for minimally invasive operations, and snowballing investments for research on novel treatments.

As per Medscape, by the age of 60, approximately 50% of the men develop histopathologic BPH. By the age of 85, this percentage rises to 90%.

One way in which BPH management has significantly benefitted from advanced technology is the introduction of procedures that do not require general anesthesia or lengthy hospital stays. The prostate can now be fitted with a cutting-edge mechanical implant, which moves the invading lobes to a better position, to improve urine flow.

Minimally Invasive Procedures Are Gaining Wide Acceptance

Surgery is a superior option to treating BPH with medicine. However, patients tend to choose medication because of the post-operative harm that surgical incisions and burns can cause. Lately, patients' perceptions have changed as a result of the development of minimally invasive techniques, thus giving surgical equipment makers a competitive advantage.

Demand for Alpha-Blockers Rising among Patients

Around 85% of the market share was acquired for drug treatment in 2021. This is due to the rising demand for alpha-blockers, which help facilitate easier urine flow by relaxing the bladder neck muscles and the prostate.

Home Healthcare Settings Will Accumulate More Revenue

Home healthcare settings hold the larger market share, and they will experience a CAGR of over 5% in the coming years. This is owing to the rising number of patients who are being prescribed medications rather than surgical procedures. Additionally, a sizeable section of the populace favors drug-based home therapy over hospital care.

North America Widely Uses BPH Treatment

North America holds a 41% share of the global BPH treatment market. The problem's prevalence is rising, encouraging the use of cutting-edge treatments, including prostatic stenting, laser therapy, and UroLift therapy.

Additionally, there are a number of device and pharmaceutical companies in the region, and they are all keenly interested in undertaking R&D operations to improve the standard of care.

With a CAGR of 6.4%, the APAC region is predicted to grow the quickest. The progress is aided by the expanding standard of living, thriving per capita income and purchasing power, rising urological illness burden, and increasing healthcare investment.

The senior male population in Japan, China, and India is huge and needs constant medical care because of its high tendency for chronic illnesses.

Product Code: 12191

Table of Contents

Chapter 1. Research Background

  • 1.1 Research Objectives
  • 1.2 Market Definition
  • 1.3 Analysis Period
  • 1.4 Market Data Reporting Unit
    • 1.4.1 Value
  • 1.5 Market Size Breakdown by Segment
    • 1.5.1 Market Segmentation by Type
    • 1.5.2 Market Segmentation by End User
    • 1.5.3 Market Segmentation by Region
  • 1.6 Key Stakeholders

Chapter 2. Research Methodology

  • 2.1 Secondary Research
    • 2.1.1 Paid
    • 2.1.2 Unpaid
    • 2.1.3 P&S Intelligence Database
  • 2.2 Primary Research
    • 2.2.1 Breakdown of Primary Research, by Designation
    • 2.2.2 Breakdown of Primary Research, by Company Type
  • 2.3 Market Size Estimation
  • 2.4 Data Triangulation
  • 2.5 Currency Conversion Rates
  • 2.6 Notes and Caveats

Chapter 3. Executive Summary

  • 3.1 U.S.
  • 3.2 Canada
  • 3.3 Germany
  • 3.4 France
  • 3.5 U.K.
  • 3.6 China
  • 3.7 Japan
  • 3.8 South Korea
  • 3.9 India

Chapter 4. Voice of Industry Experts/KOLs

Chapter 5. Definition of Market Segments

  • 5.1 By Type
    • 5.1.1 Drug Treatment
      • 5.1.1.1 Alpha blockers
        • 5.1.1.1.1 Alfuzosin
        • 5.1.1.1.2 Doxazosin
        • 5.1.1.1.3 Tamsulosin
        • 5.1.1.1.4 Silodosin
        • 5.1.1.1.5 Other alpha blockers
        • 5.1.1.2 5-Alpha reductase inhibitors
        • 5.1.1.2.1 Finasteride
        • 5.1.1.2.2 Dutasteride
      • 5.1.1.3 Others
    • 5.1.2 Surgical Treatment
      • 5.1.2.1 TURP
      • 5.1.2.2 TUMT
      • 5.1.2.3 TUNA
      • 5.1.2.4 Laser therapy
      • 5.1.2.5 Prostatic stenting
      • 5.1.2.6 UroLift therapy
      • 5.1.2.7 Rezum therapy
      • 5.1.2.8 Others
  • 5.2 By End User
    • 5.2.1 Home Healthcare
    • 5.2.2 Hospitals & Clinics

Chapter 6. Industry Outlook

  • 6.1 Market Dynamics
    • 6.1.1 Trends
      • 6.1.1.1 Technological advancements
      • 6.1.1.2 Product approvals and launches
    • 6.1.2 Drivers
      • 6.1.2.1 Increasing geriatric male population
      • 6.1.2.2 Rising prevalence of BPH
      • 6.1.2.3 Surging awareness of BPH disorders
    • 6.1.3 Impact Analysis of Drivers on Market Forecast
    • 6.1.4 Restraints
      • 6.1.4.1 Side-effects associated with BPH medication
      • 6.1.4.2 Unfavorable healthcare reforms
    • 6.1.5 Impact Analysis of Restraints on Market Forecast
  • 6.2 Impact of COVID-19
  • 6.3 Porter's Five Forces Analysis
    • 6.3.1 Bargaining Power of Buyers
    • 6.3.2 Bargaining Power of Suppliers
    • 6.3.3 Intensity of Rivalry
    • 6.3.4 Threat of New Entrants
    • 6.3.5 Threat of Substitutes

Chapter 7. Policy and Regulatory Landscape

  • 7.1 Regulations for BPH Treatment Devices
    • 7.1.1 North America
    • 7.1.2 Europe
    • 7.1.3 APAC
    • 7.1.4 LATAM
    • 7.1.5 MEA
  • 7.2 Regulatory Framework for Drug Approval
    • 7.2.1 U.S.
    • 7.2.2 Europe
      • 7.2.2.1 Centralized procedure
      • 7.2.2.2 Mutual recognition procedure
      • 7.2.2.3 Decentralized procedure
      • 7.2.2.4 Nationalized procedure
    • 7.2.3 Japan

Chapter 8. Global Market Size and Forecast

  • 8.1 Overview
  • 8.2 Market Revenue, by Type (2015-2030)
    • 8.2.1 Global Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2015-2030)
      • 8.2.1.1 Global benign prostatic hyperplasia alpha blockers market revenue, by type (2015-2030)
      • 8.2.1.2 Global benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2015-2030)
    • 8.2.2 Global Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2015-2030)
  • 8.3 Market Revenue, by End User (2015-2030)
  • 8.4 Market Revenue, by Region (2015-2030)

Chapter 9. North America Market Size and Forecast

  • 9.1 Overview
  • 9.2 Market Revenue, by Type (2015-2030)
    • 9.2.1 North America Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2015-2030)
      • 9.2.1.1 North America benign prostatic hyperplasia alpha blockers market revenue, by type (2015-2030)
      • 9.2.1.2 North America benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2015-2030)
    • 9.2.2 North America Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2015-2030)
  • 9.3 Market Revenue, by End User (2015-2030)
  • 9.4 Market Revenue, by Country (2015-2030)

Chapter 10. U.S. Market Size and Forecast

  • 10.1 Market Revenue, by Type (2015-2030)
    • 10.1.1 U.S. Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2015-2030)
      • 10.1.1.1 U.S. benign prostatic hyperplasia alpha blockers market revenue, by type (2015-2030)
      • 10.1.1.2 U.S. benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2015-2030)
    • 10.1.2 U.S. Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2015-2030)
  • 10.2 Market Revenue, by End User (2015-2030)

Chapter 11. Canada Market Size and Forecast

  • 11.1 Market Revenue, by Type (2015-2030)
    • 11.1.1 Canada Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2015-2030)
      • 11.1.1.1 Canada benign prostatic hyperplasia alpha blockers market revenue, by type (2015-2030)
      • 11.1.1.2 Canada benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2015-2030)
    • 11.1.2 Canada Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2015-2030)
  • 11.2 Market Revenue, by End User (2015-2030)

Chapter 12. Europe Market Size and Forecast

  • 12.1 Overview
  • 12.2 Market Revenue, by Type (2015-2030)
    • 12.2.1 Europe Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2015-2030)
      • 12.2.1.1 Europe benign prostatic hyperplasia alpha blockers market revenue, by type (2015-2030)
      • 12.2.1.2 Europe benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2015-2030)
    • 12.2.2 Europe Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2015-2030)
  • 12.3 Market Revenue, by End User (2015-2030)
  • 12.4 Market Revenue, by Country (2015-2030)

Chapter 13. Germany Market Size and Forecast

  • 13.1 Market Revenue, by Type (2015-2030)
    • 13.1.1 Germany Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2015-2030)
      • 13.1.1.1 Germany benign prostatic hyperplasia alpha blockers market revenue, by type (2015-2030)
      • 13.1.1.2 Germany benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2015-2030)
    • 13.1.2 Germany Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2015-2030)
  • 13.2 Market Revenue, by End User (2015-2030)

Chapter 14. France Market Size and Forecast

  • 14.1 Market Revenue, by Type (2015-2030)
    • 14.1.1 France Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2015-2030)
      • 14.1.1.1 France benign prostatic hyperplasia alpha blockers market revenue, by type (2015-2030)
      • 14.1.1.2 France benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2015-2030)
    • 14.1.2 France Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2015-2030)
  • 14.2 Market Revenue, by End User (2015-2030)

Chapter 15. U.K. Market Size and Forecast

  • 15.1 Market Revenue, by Type (2015-2030)
    • 15.1.1 U.K. Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2015-2030)
      • 15.1.1.1 U.K. benign prostatic hyperplasia alpha blockers market revenue, by type (2015-2030)
      • 15.1.1.2 U.K. benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2015-2030)
    • 15.1.2 U.K. Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2015-2030)
  • 15.2 Market Revenue, by End User (2015-2030)

Chapter 16. APAC Market Size and Forecast

  • 16.1 Overview
  • 16.2 Market Revenue, by Type (2015-2030)
    • 16.2.1 APAC Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2015-2030)
      • 16.2.1.1 APAC benign prostatic hyperplasia alpha blockers market revenue, by type (2015-2030)
      • 16.2.1.2 APAC benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2015-2030)
    • 16.2.2 APAC Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2015-2030)
  • 16.3 Market Revenue, by End User (2015-2030)
  • 16.4 Market Revenue, by Country (2015-2030)

Chapter 17. China Market Size and Forecast

  • 17.1 Market Revenue, by Type (2015-2030)
    • 17.1.1 China Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2015-2030)
      • 17.1.1.1 China benign prostatic hyperplasia alpha blockers market revenue, by type (2015-2030)
      • 17.1.1.2 China benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2015-2030)
    • 17.1.2 China Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2015-2030)
  • 17.2 Market Revenue, by End User (2015-2030)

Chapter 18. Japan Market Size and Forecast

  • 18.1 Market Revenue, by Type (2015-2030)
    • 18.1.1 Japan Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2015-2030)
      • 18.1.1.1 Japan benign prostatic hyperplasia alpha blockers market revenue, by type (2015-2030)
      • 18.1.1.2 Japan benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2015-2030)
    • 18.1.2 Japan Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2015-2030)
  • 18.2 Market Revenue, by End User (2015-2030)

Chapter 19. South Korea Market Size and Forecast

  • 19.1 Market Revenue, by Type (2015-2030)
    • 19.1.1 South Korea Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2015-2030)
      • 19.1.1.1 South Korea benign prostatic hyperplasia alpha blockers market revenue, by type (2015-2030)
      • 19.1.1.2 South Korea benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2015-2030)
    • 19.1.2 South Korea Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2015-2030)
  • 19.2 Market Revenue, by End User (2015-2030)

Chapter 20. India Market Size and Forecast

  • 20.1 Market Revenue, by Type (2015-2030)
    • 20.1.1 India Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2015-2030)
      • 20.1.1.1 India benign prostatic hyperplasia alpha blockers market revenue, by type (2015-2030)
      • 20.1.1.2 India benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2015-2030)
    • 20.1.2 India Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2015-2030)
  • 20.2 Market Revenue, by End User (2015-2030)

Chapter 21. LATAM Market Size and Forecast

  • 21.1 Overview
  • 21.2 Market Revenue, by Type (2015-2030)
    • 21.2.1 LATAM Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2015-2030)
      • 21.2.1.1 LATAM benign prostatic hyperplasia alpha blockers market revenue, by type (2015-2030)
      • 21.2.1.2 LATAM benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2015-2030)
    • 21.2.2 LATAM Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2015-2030)
  • 21.3 Market Revenue, by End User (2015-2030)
  • 21.4 Market Revenue, by Country (2015-2030)

Chapter 22. MEA Market Size and Forecast

  • 22.1 Overview
  • 22.2 Market Revenue, by Type (2015-2030)
    • 22.2.1 MEA Benign Prostatic Hyperplasia Drugs Market Revenue, by Type (2015-2030)
      • 22.2.1.1 MEA benign prostatic hyperplasia alpha blockers market revenue, by type (2015-2030)
      • 22.2.1.2 MEA benign prostatic hyperplasia 5-alpha reductase inhibitors market revenue, by type (2015-2030)
    • 22.2.2 MEA Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type (2015-2030)
  • 22.3 Market Revenue, by End User (2015-2030)
  • 22.4 Market Revenue, by Country (2015-2030)

Chapter 23. Competitive Landscape

  • 23.1 List of Market Players and Their Offerings
  • 23.2 Market Share Analysis of Key Players
    • 23.2.1 Global BPH Drugs Market
    • 23.2.2 Global BPH Surgical Treatment Market
  • 23.3 Competitive Analysis of Key Players
  • 23.4 Product Comparison of Key Players
  • 23.5 Recent Strategic Developments of Key Players
    • 23.5.1 Partnerships & Acquisitions
    • 23.5.2 Geographical Expansions
    • 23.5.3 Product Launches
    • 23.5.4 Other Developments

Chapter 24. Company Profiles

  • 24.1 Astellas Pharma Inc.
    • 24.1.1 Business Overview
    • 24.1.2 Product and Service Offerings
    • 24.1.3 Key Financial Summary
  • 24.2 Alembic Pharmaceuticals Limited
    • 24.2.1 Business Overview
    • 24.2.2 Product and Service Offerings
    • 24.2.3 Key Financial Summary
  • 24.3 Unilab Inc.
    • 24.3.1 Business Overview
    • 24.3.2 Product and Service Offerings
  • 24.4 Pharex Health Corporation
    • 24.4.1 Business Overview
    • 24.4.2 Product and Service Offerings
  • 24.5 Biolitec AG
    • 24.5.1 Business Overview
    • 24.5.2 Product and Service Offering
  • 24.6 Urologix LLC
    • 24.6.1 Business Overview
    • 24.6.2 Product and Service Offerings
  • 24.7 Advin Health Care
    • 24.7.1 Business Overview
    • 24.7.2 Product and Service Offerings
  • 24.8 Asclepion Laser Technologies GmbH
    • 24.8.1 Business Overview
    • 24.8.2 Product and Service Offerings
  • 24.9 Pnn Medical A/S
    • 24.9.1 Business Overview
    • 24.9.2 Product and Service Offerings
  • 24.10 Quanta Systems
    • 24.10.1 Business Overview
    • 24.10.2 Product and Service Offerings
  • 24.11 Abbott Laboratories
    • 24.11.1 Business Overview
    • 24.11.2 Product and Service Offerings
    • 24.11.3 Key Financial Summary
  • 24.12 Asahi Kasei Corporation
    • 24.12.1 Business Overview
    • 24.12.2 Product and Service Offerings
    • 24.12.3 Key Financial Summary
  • 24.13 Richard Wolf GmbH
    • 24.13.1 Business Overview
    • 24.13.2 Product and Service Offerings
  • 24.14 Boston Scientific Corporation
    • 24.14.1 Business Overview
    • 24.14.2 Product and Service Offerings
    • 24.14.3 Key Financial Summary
  • 24.15 KARL STORZ SE & Co. KG
    • 24.15.1 Business Overview
    • 24.15.2 Product and Service Offerings
  • 24.16 Teleflex Incorporated
    • 24.16.1 Business Overview
    • 24.16.2 Product and Service Offerings
    • 24.16.3 Key Financial Summary
  • 24.17 Olympus Corporation
    • 24.17.1 Business Overview
    • 24.17.2 Product and Service Offerings
    • 24.17.3 Key Financial Summary
  • 24.18 Pfizer Inc.
    • 24.18.1 Business Overview
    • 24.18.2 Product and Service Offerings
    • 24.18.3 Key Financial Summary
  • 24.19 Merck & Co. Inc.
    • 24.19.1 Business Overview
    • 24.19.2 Product and Service Offerings
    • 24.19.3 Key Financial Summary
  • 24.20 Eli Lilly and Company
    • 24.20.1 Business Overview
    • 24.20.2 Product and Service Offerings
    • 24.20.3 Key Financial Summary
  • 24.21 GlaxoSmithKline plc
    • 24.21.1 Business Overview
    • 24.21.2 Product and Service Offerings
    • 24.21.3 Key Financial Summary
  • 24.22 Allergan plc
    • 24.22.1 Business Overview
    • 24.22.2 Product and Service Offerings
    • 24.22.3 Key Financial Summary
  • 24.23 IPG Photonics Corporation
    • 24.23.1 Business Overview
    • 24.23.2 Product and Service Offerings
    • 24.23.3 Key Financial Summary
  • 24.24 Sanofi
    • 24.24.1 Business Overview
    • 24.24.2 Product and Service Offerings
    • 24.24.3 Key Financial Summary
  • 24.25 Allium Medical Solutions Ltd.
    • 24.25.1 Business Overview
    • 24.25.2 Product and Service Offerings
  • 24.26 SRS Medical
    • 24.26.1 Business Overview
    • 24.26.2 Product and Service Offerings
  • 24.27 Convergent Laser Technologies
    • 24.27.1 Business Overview
    • 24.27.2 Product and Service Offerings

Chapter 25. Appendix

  • 25.1 Sources and References
  • 25.2 Related Reports
Product Code: 12191

LIST OF FIGURES

  • FIG 1 MARKET SIZE BREAKDOWN BY SEGMENT
  • FIG 2 RESEARCH METHODOLOGY
  • FIG 3 BREAKDOWN OF PRIMARY RESEARCH, BY DESIGNATION
  • FIG 4 BREAKDOWN OF PRIMARY RESEARCH, BY COMPANY TYPE
  • FIG 5 DATA TRIANGULATION APPROACH
  • FIG 6 U.S. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SUMMARY
  • FIG 7 CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SUMMARY
  • FIG 8 GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SUMMARY
  • FIG 9 FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SUMMARY
  • FIG 10 U.K. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SUMMARY
  • FIG 11 CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SUMMARY
  • FIG 12 JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SUMMARY
  • FIG 13 SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SUMMARY
  • FIG 14 INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SUMMARY
  • FIG 15 VOICE OF INDUSTRY EXPERTS/KOLS
  • FIG 16 BARGAINING POWER OF BUYERS
  • FIG 17 BARGAINING POWER OF SUPPLIERS
  • FIG 18 INTENSITY OF RIVALRY
  • FIG 19 THREAT OF NEW ENTRANTS
  • FIG 20 THREAT OF SUBSTITUTES
  • FIG 21 DRUG DISCOVERY AND APPROVAL PROCESS (PRE-CLINICAL AND CLINICAL TRIAL STAGES)
  • FIG 22 DRUG APPROVAL PROCESS (NDA REVIEW AND POST-MARKETING STAGES)
  • FIG 23 NEW DRUG DEVELOPMENT AND APPROVAL PROCESS IN EU
  • FIG 24 MARKETING AUTHORIZATION PROCEDURES IN EU
  • FIG 25 CENTRALIZED PROCEDURE FOR DRUG APPROVAL
  • FIG 26 DECENTRALIZED PROCEDURE FOR DRUG APPROVAL
  • FIG 27 NEW DRUG DEVELOPMENT AND APPROVAL PROCESS IN JAPAN
  • FIG 28 GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SNAPSHOT
  • FIG 29 GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 30 GLOBAL BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 31 GLOBAL BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 32 GLOBAL BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 33 GLOBAL BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 34 GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2015-2030)
  • FIG 35 GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY REGION, $M (2015-2030)
  • FIG 36 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SNAPSHOT
  • FIG 37 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 38 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 39 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 40 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 41 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 42 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2015-2030)
  • FIG 43 NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY COUNTRY, $M (2015-2030)
  • FIG 44 U.S. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 45 U.S. BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 46 U.S. BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 47 U.S. BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 48 U.S. BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 49 U.S. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2015-2030)
  • FIG 50 CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 51 CANADA BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 52 CANADA BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 53 CANADA BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 54 CANADA BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 55 CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2015-2030)
  • FIG 56 EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SNAPSHOT
  • FIG 57 EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 58 EUROPE BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 59 EUROPE BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 60 EUROPE BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 61 EUROPE BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 62 EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2015-2030)
  • FIG 63 EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY COUNTRY, $M (2015-2030)
  • FIG 64 GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 65 GERMANY BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 66 GERMANY BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 67 GERMANY BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 68 GERMANY BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 69 GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2015-2030)
  • FIG 70 FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 71 FRANCE BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 72 FRANCE BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 73 FRANCE BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 74 FRANCE BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 75 FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2015-2030)
  • FIG 76 U.K. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 77 U.K. BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 78 U.K. BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 79 U.K. BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 80 U.K. BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 81 U.K. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2015-2030)
  • FIG 82 APAC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SNAPSHOT
  • FIG 83 APAC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 84 APAC BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 85 APAC BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 86 APAC BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 87 APAC BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 88 APAC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2015-2030)
  • FIG 89 APAC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY COUNTRY, $M (2015-2030)
  • FIG 90 CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 91 CHINA BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 92 CHINA BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 93 CHINA BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 94 CHINA BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 95 CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2015-2030)
  • FIG 96 JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 97 JAPAN BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 98 JAPAN BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 99 JAPAN BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 100 JAPAN BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 101 JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2015-2030)
  • FIG 102 SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 103 SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 104 SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 105 SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 106 SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 107 SOUTH KOREA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2015-2030)
  • FIG 108 INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 109 INDIA BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 110 INDIA BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 111 INDIA BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 112 INDIA BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 113 INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2015-2030)
  • FIG 114 LATAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SNAPSHOT
  • FIG 115 LATAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 116 LATAM BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 117 LATAM BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 118 LATAM BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 119 LATAM BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 120 LATAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2015-2030)
  • FIG 121 LATAM BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY COUNTRY, $M (2015-2030)
  • FIG 122 MEA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SNAPSHOT
  • FIG 123 MEA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 124 MEA BENIGN PROSTATIC HYPERPLASIA DRUGS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 125 MEA BENIGN PROSTATIC HYPERPLASIA ALPHA BLOCKERS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 126 MEA BENIGN PROSTATIC HYPERPLASIA 5-ALPHA REDUCTASE INHIBITORS MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 127 MEA BENIGN PROSTATIC HYPERPLASIA SURGICAL TREATMENT MARKET REVENUE, BY TYPE, $M (2015-2030)
  • FIG 128 MEA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY END USER, $M (2015-2030)
  • FIG 129 MEA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET REVENUE, BY COUNTRY, $M (2015-2030)
  • FIG 130 GLOBAL BPH DRUGS MARKET SHARE OF KEY PLAYERS (2021)
  • FIG 131 GLOBAL BPH SURGICAL TREATMENT MARKET SHARE OF KEY PLAYERS (2021)
  • FIG 132 ASTELLAS PHARMA INC. - REVENUE SPLIT BY GEOGRAPHY (2021)
  • FIG 133 ALEMBIC PHARMACEUTICALS LIMITED - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2021)
  • FIG 134 ABBOTT LABORATORIES - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2021)
  • FIG 135 ASAHI KASEI CORPORATION - REVENUE SPLIT BY BUSINESS SECTOR AND GEOGRAPHY (2021)
  • FIG 136 BOSTON SCIENTIFIC CORPORATION - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2021)
  • FIG 137 TELEFLEX INCORPORATED - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2021)
  • FIG 138 OLYMPUS CORPORATION - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2021)
  • FIG 139 PFIZER INC. - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2021)
  • FIG 140 MERCK & CO. INC. - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2021)
  • FIG 141 ELI LILLY AND COMPANY - REVENUE SPLIT BY THERAPEUTIC AREA AND GEOGRAPHY (2021)
  • FIG 142 GLAXOSMITHKLINE PLC - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2021)
  • FIG 143 ALLERGAN PLC - REVENUE SPLIT BY SEGMENT (2019)
  • FIG 144 IPG PHOTONICS CORPORATION - REVENUE SPLIT BY GEOGRAPHY (2021)
  • FIG 145 SANOFI - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2020)
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!